Last €0.50 EUR
Change Today +0.004 / 0.81%
Volume 13.9M
PHARM On Other Exchanges
EN Amsterdam
As of 11:35 AM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

pharming group nv (PHARM) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/18/14 - €0.73
52 Week Low
04/24/13 - €0.06
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PHARMING GROUP NV (PHARM)

Related News

No related news articles were found.

pharming group nv (PHARM) Related Businessweek News

No Related Businessweek News Found

pharming group nv (PHARM) Details

Pharming Group NV develops protein therapeutics for the treatment of genetic disorders, specialty products for surgical indications, intermediates for various medical applications, and nutritional products. It offers RUCONEST (conestat alfa), a recombinant human C1 esterase inhibitor for the treatment of angioedema attacks in patients with HAE in the European Union countries; Norway, Iceland, and Liechtenstein; and North America. The company was formerly known as Gene Pharming Europe B.V. Pharming Group NV was founded in 1988 and is based in Leiden, the Netherlands.

40 Employees
Last Reported Date: 03/6/14
Founded in 1988

pharming group nv (PHARM) Top Compensated Officers

Chief Executive Officer and Member of Managem...
Total Annual Compensation: €594.0K
Chief Operations Officer and Member of Manage...
Total Annual Compensation: €346.0K
Compensation as of Fiscal Year 2012.

pharming group nv (PHARM) Key Developments

Pharming Group NV(ENXTAM:PHARM) dropped from AMX Index

Pharming Group NV will be removed from the AMX Index.

Pharming Group NV, 2013 Earnings Call, Mar 06, 2014

Pharming Group NV, 2013 Earnings Call, Mar 06, 2014

Pharming Group NV Reports Preliminary Unaudited Earnings Results for the Year Ended December 31, 2013

Pharming Group NV reported preliminary unaudited earnings results for the year ended December 31, 2013. For year, the company reported revenues and other income decreased to EUR 7.0 million from EUR 10.9 million in 2012 mainly as a result from lower license fees as 2012 included receipt of a EUR 7.9 million milestone from Santarus for successful completion of study 1310 while 2013 included a EUR 3.8 milestone from Santarus for acceptance for review of the BLA for Ruconest by the US FDA. Sales increased to EUR 0.9 million from EUR 0.8 million in 2012. Total net loss attributable to owners of the parent decreased to EUR 14.8 million from EUR 24.1 million in 2012 as result of a reduction in the loss from operating activities to EUR 6.9 million from EUR 17.5 million in 2012. Net cash outflows from operations decreased to EUR 8.3 million from EUR 10.3 million in 2012. Purchase of property, plant and equipment was EUR 21,000 against EUR 614,000 a year ago. Net loss from continuing operations was EUR 14,840,000 or EUR 0.070 per basic share, compared to EUR 24,093,000 or EUR 0.330 per basic share a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PHARM:NA €0.50 EUR +0.004

PHARM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €8.85 EUR +0.099
BioCryst Pharmaceuticals Inc $8.55 USD -0.65
Dyax Corp $6.84 USD -0.43
Oxford Biomedica PLC 2.17 GBp -0.03
Swedish Orphan Biovitrum AB kr68.70 SEK +0.95
View Industry Companies

Industry Analysis


Industry Average

Valuation PHARM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 23.7x
Price/Book 37.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 24.4x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMING GROUP NV, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at